Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma
- PMID: 1828183
- DOI: 10.1111/j.1464-410x.1991.tb15195.x
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma
Erratum in
- Br J Urol 1993 May;71(5):632
Abstract
Between November 1983 and February 1986, 358 patients with previously untreated metastatic prostatic carcinoma entered a multicentre, randomised trial in the United Kingdom and the Republic of Ireland, in which the LHRH analogue Zoladex (ICI Pharmaceuticals PLC), administered subcutaneously every 28 days, was compared with orchiectomy. Both treatments were equally effective in lowering serum testosterone concentrations to within the surgically castrate range and this was accompanied by equivalent subjective and objective response rates and times to treatment failure. At a median follow-up of 2 years there was no difference in overall survival, confirming that Zoladex is an effective medical alternative to orchiectomy in patients with metastatic disease.
Comment in
-
Re: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. A. V. Kaisary et al. Br. J. Urol., 67, 502-508, 1991.Br J Urol. 1992 Apr;69(4):441-2. Br J Urol. 1992. PMID: 1533812 No abstract available.
Similar articles
-
Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.Urology. 1989 May;33(5 Suppl):45-52. doi: 10.1016/0090-4295(89)90106-4. Urology. 1989. PMID: 2523611 Clinical Trial.
-
U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.Am J Clin Oncol. 1988;11 Suppl 2:S169-72. doi: 10.1097/00000421-198801102-00039. Am J Clin Oncol. 1988. PMID: 2977272 Clinical Trial.
-
Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.Urology. 1991 Jan;37(1):17-21. doi: 10.1016/0090-4295(91)80070-n. Urology. 1991. PMID: 1702566
-
Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.Urology. 1989 May;33(5 Suppl):42-4. doi: 10.1016/0090-4295(89)90105-2. Urology. 1989. PMID: 2523610 Review.
-
Trials and tribulations in prostatic cancer.Br J Urol. 1987 May;59(5):375-9. doi: 10.1111/j.1464-410x.1987.tb04828.x. Br J Urol. 1987. PMID: 3297229 Review. No abstract available.
Cited by
-
Intermittent androgen deprivation therapy: redefining the standard of care?Rev Urol. 2010 Winter;12(1):1-11. Rev Urol. 2010. PMID: 20428288 Free PMC article.
-
Early versus late hormonal therapy for prostate cancer.Curr Urol Rep. 2004 Jun;5(3):188-96. doi: 10.1007/s11934-004-0036-4. Curr Urol Rep. 2004. PMID: 15161567 Review.
-
[Therapy of nodal positive prostatic carcinoma: when should hormone therapy be started?].Strahlenther Onkol. 1998 Jul;174(7):382-3. doi: 10.1007/BF03038354. Strahlenther Onkol. 1998. PMID: 9689961 Clinical Trial. German. No abstract available.
-
Quality of life and economic considerations in the management of prostate cancer.Pharmacoeconomics. 2003;21(8):527-41. doi: 10.2165/00019053-200321080-00001. Pharmacoeconomics. 2003. PMID: 12751912 Review.
-
Prostate cancer: a comprehensive review.Med Oncol. 2000 May;17(2):85-105. doi: 10.1007/BF02796203. Med Oncol. 2000. PMID: 10871814 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical